miR-579-3p controls melanoma progression and resistance to target therapy

Therapy of melanoma patients harboring activating mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) oncogene with a combination of BRAF and MEK inhibitors is plagued by the development of drug resistance. Mutational events, as well as adaptive mechanisms, contribute to the devel...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Proc Natl Acad Sci U S A
Prif Awduron: Fattore, Luigi, Mancini, Rita, Acunzo, Mario, Romano, Giulia, Laganà, Alessandro, Pisanu, Maria Elena, Malpicci, Debora, Madonna, Gabriele, Mallardo, Domenico, Capone, Marilena, Fulciniti, Franco, Mazzucchelli, Luca, Botti, Gerardo, Croce, Carlo M., Ascierto, Paolo Antonio, Ciliberto, Gennaro
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: National Academy of Sciences 2016
Pynciau:
PNAS Plus
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5003278/
https://ncbi.nlm.nih.gov/pubmed/27503895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607753113
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg